Symbols / OLMA Stock $15.29 -1.55% Olema Pharmaceuticals, Inc.
OLMA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Ratings
Current target
$15.29
Low
$27.00
High
$62.00
Mean
$43.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | init | Wolfe Research | — → Peer Perform | — |
| 2026-03-18 | main | JP Morgan | Overweight → Overweight | $58 |
| 2026-03-18 | main | Goldman Sachs | Buy → Buy | $27 |
| 2026-03-17 | main | Citigroup | Buy → Buy | $62 |
| 2026-03-17 | main | Guggenheim | Buy → Buy | $38 |
| 2026-03-09 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2026-02-11 | init | Stifel | — → Buy | $48 |
| 2026-01-07 | init | UBS | — → Buy | $45 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | — |
| 2025-12-12 | main | Citigroup | Buy → Buy | $60 |
| 2025-12-11 | main | Oppenheimer | Outperform → Outperform | $48 |
| 2025-12-11 | main | Goldman Sachs | Buy → Buy | $38 |
| 2025-12-11 | main | HC Wainwright & Co. | Buy → Buy | $45 |
| 2025-11-21 | main | Goldman Sachs | Buy → Buy | $26 |
| 2025-11-18 | main | Oppenheimer | Outperform → Outperform | $45 |
| 2025-11-18 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $32 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2025-10-08 | init | Guggenheim | — → Buy | $20 |
| 2025-09-03 | main | Oppenheimer | Outperform → Outperform | $22 |
- Olema Pharmaceuticals (OLMA) Valuation Check After New Palazestrant And OP-3136 Preclinical Results - simplywall.st Mon, 27 Apr 2026 08
- OLMA Forecast, Price Target & Analyst Ratings | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill hu, 23 Apr 2026 07
- Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN Sat, 25 Apr 2026 18
- Olema brings first human OP-3136 cancer trial results to ASCO - Stock Titan ue, 21 Apr 2026 20
- $OLMA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 07
- Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat Wed, 22 Apr 2026 08
- Olema Pharmaceuticals (OLMA) to Showcase Phase 1 Study Results a - GuruFocus Wed, 22 Apr 2026 00
- OLMA (Olema Pharmaceuticals Inc.) posts narrow Q4 2025 EPS beat, sending shares up two percent in daily trading. - Consensus Forecast - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 22
- Four new Olema hires receive stock options for 188,500 shares - Stock Titan hu, 02 Apr 2026 07
- Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT - Yahoo Finance hu, 11 Dec 2025 08
- Olema Pharmaceuticals Stock (OLMA) Opinions on Strategic Collaboration Announcement | OLMA Stock News - Quiver Quantitative ue, 18 Nov 2025 08
- Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? - Yahoo Finance Wed, 19 Nov 2025 08
- Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One‑Year Surge? - Yahoo Finance ue, 17 Feb 2026 08
- Olema Pharmaceuticals (OLMA) Is Up 5.6% After Preclinical Data Highlight Deeper ER Blockade Potential - simplywall.st ue, 21 Apr 2026 02
- A Look At Olema Pharmaceuticals (OLMA) Valuation After New Preclinical Breast Cancer Data - simplywall.st Sun, 19 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
178.70
+25.62%
|
142.26
+35.53%
|
104.96
-1.89%
|
106.99
|
| Research And Development |
|
157.70
+26.65%
|
124.52
+44.55%
|
86.14
+4.70%
|
82.27
|
| Selling General And Administration |
|
21.00
+18.38%
|
17.74
-5.74%
|
18.82
-23.84%
|
24.71
|
| General And Administrative Expense |
|
21.00
+18.38%
|
17.74
-5.74%
|
18.82
-23.84%
|
24.71
|
| Other Gand A |
|
21.00
+18.38%
|
17.74
-5.74%
|
18.82
-23.84%
|
24.71
|
| Total Expenses |
|
178.70
+25.62%
|
142.26
+35.53%
|
104.96
-1.89%
|
106.99
|
| Operating Income |
|
-178.70
-25.62%
|
-142.26
-35.53%
|
-104.96
+1.89%
|
-106.99
|
| Total Operating Income As Reported |
|
-178.70
-25.62%
|
-142.26
-35.53%
|
-104.96
+1.89%
|
-106.99
|
| EBITDA |
|
-178.21
-25.62%
|
-141.87
-35.65%
|
-104.58
+1.92%
|
-106.63
|
| Normalized EBITDA |
|
-178.21
-25.62%
|
-141.87
-35.65%
|
-104.58
+1.92%
|
-106.63
|
| Reconciled Depreciation |
|
0.49
+24.68%
|
0.39
+4.24%
|
0.38
+5.60%
|
0.36
|
| EBIT |
|
-178.70
-25.62%
|
-142.26
-35.53%
|
-104.96
+1.89%
|
-106.99
|
| Net Income |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Pretax Income |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Net Non Operating Interest Income Expense |
|
16.22
+27.93%
|
12.68
+52.34%
|
8.32
+273.65%
|
2.23
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
16.22
+27.93%
|
12.68
+52.34%
|
8.32
+273.65%
|
2.23
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
16.22
+27.93%
|
12.68
+52.34%
|
8.32
+273.65%
|
2.23
|
| Interest Income |
|
16.22
+27.93%
|
12.68
+52.34%
|
8.32
+273.65%
|
2.23
|
| Other Income Expense |
|
0.02
-77.45%
|
0.10
+636.84%
|
-0.02
+29.63%
|
-0.03
|
| Other Non Operating Income Expenses |
|
0.02
-77.45%
|
0.10
+636.84%
|
-0.02
+29.63%
|
-0.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Net Income From Continuing Operation Net Minority Interest |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Net Income From Continuing And Discontinued Operation |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Net Income Continuous Operations |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Normalized Income |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Net Income Common Stockholders |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-2.20
-2.80%
|
-2.14
+18.32%
|
-2.62
|
| Basic EPS |
|
—
|
-2.20
-2.80%
|
-2.14
+18.32%
|
-2.62
|
| Basic Average Shares |
|
—
|
58.74
+29.83%
|
45.25
+13.13%
|
40.00
|
| Diluted Average Shares |
|
—
|
58.74
+29.83%
|
45.25
+13.13%
|
40.00
|
| Diluted NI Availto Com Stockholders |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
276.94
|
| Current Assets |
|
266.51
|
| Cash Cash Equivalents And Short Term Investments |
|
261.81
|
| Cash And Cash Equivalents |
|
68.54
|
| Other Short Term Investments |
|
193.27
|
| Receivables |
|
0.67
|
| Taxes Receivable |
|
—
|
| Accrued Interest Receivable |
|
0.67
|
| Prepaid Assets |
|
2.35
|
| Other Current Assets |
|
1.68
|
| Total Non Current Assets |
|
10.43
|
| Net PPE |
|
3.26
|
| Gross PPE |
|
3.26
|
| Accumulated Depreciation |
|
—
|
| Machinery Furniture Equipment |
|
—
|
| Other Properties |
|
3.26
|
| Non Current Prepaid Assets |
|
7.17
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
23.05
|
| Current Liabilities |
|
21.62
|
| Payables And Accrued Expenses |
|
15.17
|
| Payables |
|
2.77
|
| Accounts Payable |
|
2.70
|
| Current Accrued Expenses |
|
12.40
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.46
|
| Total Tax Payable |
|
0.07
|
| Current Debt And Capital Lease Obligation |
|
0.99
|
| Current Capital Lease Obligation |
|
0.99
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
1.43
|
| Long Term Debt And Capital Lease Obligation |
|
1.43
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
1.43
|
| Stockholders Equity |
|
253.90
|
| Common Stock Equity |
|
253.90
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
55.10
|
| Ordinary Shares Number |
|
54.99
|
| Treasury Shares Number |
|
0.10
|
| Additional Paid In Capital |
|
559.18
|
| Retained Earnings |
|
-305.63
|
| Gains Losses Not Affecting Retained Earnings |
|
0.35
|
| Other Equity Adjustments |
|
0.35
|
| Total Equity Gross Minority Interest |
|
253.90
|
| Total Capitalization |
|
253.90
|
| Working Capital |
|
244.89
|
| Invested Capital |
|
253.90
|
| Total Debt |
|
2.42
|
| Capital Lease Obligations |
|
2.42
|
| Net Tangible Assets |
|
253.90
|
| Tangible Book Value |
|
253.90
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-146.72
-40.60%
|
-104.35
-24.63%
|
-83.73
-2.03%
|
-82.06
|
| Cash Flow From Continuing Operating Activities |
|
-146.72
-40.60%
|
-104.35
-24.63%
|
-83.73
-2.03%
|
-82.06
|
| Net Income From Continuing Operations |
|
-162.45
-25.47%
|
-129.47
-33.95%
|
-96.66
+7.76%
|
-104.79
|
| Depreciation Amortization Depletion |
|
0.49
+24.68%
|
0.39
+4.24%
|
0.38
+5.60%
|
0.36
|
| Depreciation And Amortization |
|
0.49
+24.68%
|
0.39
+4.24%
|
0.38
+5.60%
|
0.36
|
| Other Non Cash Items |
|
-5.12
+27.17%
|
-7.03
-66.19%
|
-4.23
-922.37%
|
0.51
|
| Stock Based Compensation |
|
17.59
-22.12%
|
22.58
+30.86%
|
17.26
-8.35%
|
18.83
|
| Operating Gains Losses |
|
—
|
0.01
-91.89%
|
0.11
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
-91.89%
|
0.11
|
0.00
|
| Change In Working Capital |
|
2.77
-69.72%
|
9.16
+1655.86%
|
-0.59
-119.49%
|
3.02
|
| Change In Prepaid Assets |
|
-5.42
-1162.94%
|
-0.43
-161.82%
|
0.69
+135.43%
|
-1.96
|
| Change In Payables And Accrued Expense |
|
4.60
+83.19%
|
2.51
+8.00%
|
2.32
+562.11%
|
0.35
|
| Change In Payable |
|
4.60
+83.19%
|
2.51
+8.00%
|
2.32
+562.11%
|
0.35
|
| Change In Account Payable |
|
4.60
+83.19%
|
2.51
+8.00%
|
2.32
+562.11%
|
0.35
|
| Change In Other Current Assets |
|
-6.14
-107.81%
|
-2.96
+44.46%
|
-5.32
-377.92%
|
-1.11
|
| Change In Other Current Liabilities |
|
9.74
-2.99%
|
10.04
+484.74%
|
1.72
-70.11%
|
5.74
|
| Investing Cash Flow |
|
-155.76
-66.54%
|
-93.53
-1827.97%
|
-4.85
-105.30%
|
91.48
|
| Cash Flow From Continuing Investing Activities |
|
-155.76
-66.54%
|
-93.53
-1827.97%
|
-4.85
-105.30%
|
91.48
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.16
-1235.71%
|
0.01
+103.86%
|
-0.36
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.16
|
0.00
+100.00%
|
-0.36
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Capital Expenditure |
|
—
|
-0.16
|
—
|
-0.36
|
| Net Investment Purchase And Sale |
|
-155.76
-66.83%
|
-93.37
-1819.16%
|
-4.87
-105.30%
|
91.84
|
| Purchase Of Investment |
|
-500.72
-26.78%
|
-394.96
-54.51%
|
-255.62
-19.64%
|
-213.66
|
| Sale Of Investment |
|
344.96
+14.38%
|
301.59
+20.27%
|
250.76
-17.92%
|
305.50
|
| Financing Cash Flow |
|
211.30
-21.40%
|
268.82
+101.49%
|
133.41
+27928.36%
|
0.48
|
| Cash Flow From Continuing Financing Activities |
|
211.30
-21.40%
|
268.82
+101.49%
|
133.41
+27928.36%
|
0.48
|
| Net Issuance Payments Of Debt |
|
3.00
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
3.00
|
0.00
|
—
|
—
|
| Long Term Debt Issuance |
|
3.00
|
0.00
|
—
|
—
|
| Net Long Term Debt Issuance |
|
3.00
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
205.39
-22.87%
|
266.29
+105.25%
|
129.74
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
9.42
+272.37%
|
2.53
-31.23%
|
3.68
+672.90%
|
0.48
|
| Net Other Financing Charges |
|
-6.51
|
—
|
—
|
—
|
| Changes In Cash |
|
-91.18
-228.53%
|
70.94
+58.22%
|
44.84
+353.36%
|
9.89
|
| Beginning Cash Position |
|
139.48
+103.50%
|
68.54
+189.17%
|
23.70
+71.60%
|
13.81
|
| End Cash Position |
|
48.30
-65.37%
|
139.48
+103.50%
|
68.54
+189.17%
|
23.70
|
| Free Cash Flow |
|
-146.72
-40.38%
|
-104.51
-24.82%
|
-83.73
-1.58%
|
-82.43
|
| Amortization Of Securities |
|
—
|
—
|
—
|
-0.79
|
| Common Stock Issuance |
|
205.39
-22.87%
|
266.29
+105.25%
|
129.74
|
0.00
|
| Issuance Of Capital Stock |
|
205.39
-22.87%
|
266.29
+105.25%
|
129.74
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-16 View
- 8-K2026-03-16 View
- 42026-03-05 View
- 42026-02-17 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 8-K2026-01-30 View
- 42026-01-21 View
- 42026-01-16 View
- 42026-01-15 View
- 42026-01-14 View
- 8-K2026-01-12 View
- 42025-12-30 View
- 42025-12-29 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|